Ethybenztropine_product_DataBase

Bioactivity	Ethybenztropine (Ponalid) is a muscarinic receptor blocker. Ethybenztropine is an anticholinergic and antihistaminergic agent[1].
Target	Muscarinic Receptor
Invitro	Ethybenztropine (10 μM) inhibits the uptake of 3H-DA in neostriatal slices.
In Vivo	Ethybenztropine (25 μg, microinjected into mesencephalic NRM) blocks the hypertherrnic response of carbachol microinjection into nucleus raphe median (NRM) of rabbits[1].Ethybenztropine (30-60 μg/kg, administered by the fourth ventricle) is effective in preventing arrhythmias in dogs[2].Ethybenztropine (50 mg/kg, i.p.) reduces the catecholamines accumulation in rats[3]. Animal Model:
Name	Ethybenztropine
CAS	524-83-4
Formula	C22H27NO
Molar Mass	321.46
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. A K Saxena, et al. Presence of cholinoceptors in mesencephalic raphe nuclei concerned in thermoregulation in rabbits. Clin Exp Pharmacol Physiol. 1984 Mar-Apr;11(2):105-10. [2]. M Rozear, et al. Effects of intracerebroventricular l-hyoscyamine, ethybenztropine and procaine on cardiac arrhythmias induced in dogs by pentylenetetrazol, picrotoxin or deslanoside. Int J Neuropharmacol. 1968 Jan;7(1):1-6. [3]. LARS-OVE FARNEBO, et al. Effect of some antiparkinsonian drugs on catecholamine neurons. Journal of Pharmacy and Pharmacology, 1970, 22(10): 733-737.

PeptideDB